Press Release

Sep 15, 2022
Cytox and Thermo Fisher Scientific collaboration highlights the potential of predictive genomics to enable pre-emptive healthcare

An interview with Cytox CEO, Dr Richard Pither, in the September issue of The Journal of Precision Medicine ( highlights the benefits to healthcare provision of gene-based technologies that enable a greater understanding of the genetics behind diseases and identification of those at risk of developing a condition in the future. Cytox’s genoSCORE™  test uses a simple saliva sample to assess the genetic risk of cognitive decline due to Alzheimer’s disease. The result is a single genetic risk score that is easy to interpret. Even though an individual’s genetic risk may be high, Dr Pither emphasised that ‘patient-modifiable factors account for more than 40% of the risk for dementia, making mounting evidence that lifestyle interventions play a significant role in maintaining cognition and function as well as preventing or delaying the onset of disease, and so, behavioural changes can make a difference. Chad Carter, VP and General Manager of microarray genetic solutions at TFS said ‘with the widely accepted science that genes and genetics control a significant part of our health, we must raise the question: why are we ignoring half of the puzzle? It’s time to make predictive genomics part of the standard of care'.

About Cytox (

Without new drug therapies, the economic and healthcare cost burden of dementia - including Alzheimer's disease (AD) - is estimated to exceed $1tn per year in the next decade2.  AD – a highly complex disease with risk factors based in genetics, lifestyle, age, and environment. Cytox’s products technology genoSCORE™ and genoTOR™ use Polygenic Risk Scoring (PRS) to predict the risk of individuals developing AD, and to improve clinical trial outcomes through patient stratification and the genetic characterisation of the disease.

About genoSCORE™

The genoSCORE technology underpins non-invasive, genetic tests to assess the risk of cognitive decline due to Alzheimer’s disease (AD). The test, which uses a simple blood or saliva sample, analyses over 100,000 single nucleotide polymorphisms (SNPs) - small genetic variations - that are associated with AD. As such, the test generates a patient-specific polygenic risk score (PRS). 

Developers of new AD drug therapies can also the test to identify and recruit patients to clinical studies, ensuring the selection of the most suitable candidates, those most likely to experience cognitive decline over the time period of the study.

About Alzheimer’s Risk Test

In the United States, Sampled Smart Labs, Piscataway, New Jersey  have developed the Alzheimer’s Risk Test, powered by genoSCORE™ 

Clinicians can use the test to assess patients for the risk of developing Alzheimer's disease, before symptoms arise, prior to invasive cerebrospinal fluid (CSF) testing or expensive scanning techniques. Furthermore, the test’s simplicity of use would enable elderly and vulnerable patients self-isolating due to COVID-19, or not wishing or easily able to attend healthcare settings, to provide a suitable sample from home.